Want to see ARTL full AI Analyst Report?
ARTL Stock Chart & Stats
$1.24
-$0.05(-4.59%)
At close: 4:00 PM EST
$1.24
-$0.05(-4.59%)
Day’s Range― - ―
52-Week Range$0.96 - $49.32
Previous CloseN/A
Volume8.82K
Average Volume (3M)89.20K
Market Cap
$3.97M
Enterprise Value-$3.95
Total Cash (Recent Filing)$10.27M
Total Debt (Recent Filing)$719.00K
Price to Earnings (P/E)―
Beta-0.73
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.23
Shares Outstanding3,485,540
10 Day Avg. Volume70,584
30 Day Avg. Volume89,202
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-9.84
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical MilestonesArtelo's pipeline candidates are slated to reach important clinical milestones, which are underappreciated.
Investigational DrugART27.13 is emerging as a high-value investigational drug, as no therapies have proven to be safe treatments and approved for cancer-related cachexia.
Bears Say
Investment RisksInvestment thesis risks include failure of clinical trials to prove efficacy and potential need to raise additional funds.
Artelo Biosciences News
ARTL FAQ
What was Artelo Biosciences Inc’s price range in the past 12 months?
Artelo Biosciences Inc lowest stock price was $0.96 and its highest was $49.32 in the past 12 months.
What is Artelo Biosciences Inc’s market cap?
Artelo Biosciences Inc’s market cap is $3.97M.
When is Artelo Biosciences Inc’s upcoming earnings report date?
Artelo Biosciences Inc’s upcoming earnings report date is Aug 12, 2026 which is in 26 days.
How were Artelo Biosciences Inc’s earnings last quarter?
Artelo Biosciences Inc released its earnings results on May 14, 2026. The company reported -$4 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Artelo Biosciences Inc overvalued?
According to Wall Street analysts Artelo Biosciences Inc’s price is currently Overvalued.
Does Artelo Biosciences Inc pay dividends?
Artelo Biosciences Inc does not currently pay dividends.
What is Artelo Biosciences Inc’s EPS estimate?
Artelo Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Artelo Biosciences Inc have?
Artelo Biosciences Inc has 3,485,540 shares outstanding.
What happened to Artelo Biosciences Inc’s price movement after its last earnings report?
Artelo Biosciences Inc reported an EPS of -$4 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -21.368%.
Which hedge fund is a major shareholder of Artelo Biosciences Inc?
Currently, no hedge funds are holding shares in ARTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Artelo Biosciences Inc
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
Technical Analysis
Biodexa Pharmaceuticals
―
Theriva Biologics
―
―
Indaptus Therapeutics
―
Enveric Biosciences
―
Ownership Overview
9.46%
Insiders
0.04% Mutual Funds
0.38% Other Institutional Investors
89.82% Public Companies and
Individual Investors